» Articles » PMID: 30521382

MMP14 Empowers Tumor-initiating Breast Cancer Cells Under Hypoxic Nutrient-depleted Conditions

Overview
Journal FASEB J
Specialties Biology
Physiology
Date 2018 Dec 7
PMID 30521382
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor-initiating cells (TICs) existing in breast cancer are thought to be involved in initiation, progression, and relapse of tumors. In these processes, the epithelial-to-mesenchymal transition (EMT) and proteases are crucial factors that also dependent on the tumor milieu, including hypoxic nutrient-deprived, as well as normoxic nutrient-rich, environments. Therefore, we investigated EMT and proteases in TICs and their response to different environments by means of a newly generated immortalized TIC (iTIC) line. With the use of primary CD24CD90CD45 TICs from the mouse mammary tumor virus-polyoma middle T mouse breast cancer model, iTICs were generated by single cell-initiated sphere and subsequent 2-dimensional monolayer culture. Our data demonstrate the possibility to generate iTICs that are highly tumorigenic in culture and in mouse mammary fat pad. Contrasting environmental conditions provide these cells with a phenotypic and molecular plasticity that has a growth-promoting character in nutrient-rich normoxia and a motile character in nutrient-deprived hypoxia. Expression profiling revealed partial and dynamically changing EMT states, as well as a significantly up-regulated proteolytic signature, including many metalloproteinases, such as matrix metalloproteinase 14 ( Mmp14). Inhibitor treatment of metalloproteinases, as well as short hairpin RNA-mediated knockdown of Mmp14 strongly impacted TIC characteristics, including tumor initiation, cell growth, migration, and invasion, especially in starved environments. We conclude that metalloproteinases empower TICs to adapt to changing environments.-Hillebrand, L. E., Wickberg, S. M., Gomez-Auli, A., Follo, M., Maurer, J., Busch, H., Boerries, M., Reinheckel, T. MMP14 empowers tumor-initiating breast cancer cells under hypoxic nutrient-depleted conditions.

Citing Articles

Matrix metalloproteinases as therapeutic targets in breast cancer.

Kwon M Front Oncol. 2023; 12:1108695.

PMID: 36741729 PMC: 9897057. DOI: 10.3389/fonc.2022.1108695.


Degradome-focused RNA interference screens to identify proteases important for breast cancer cell growth.

Holzen L, Syre K, Mitschke J, Brummer T, Miething C, Reinheckel T Front Oncol. 2022; 12:960109.

PMID: 36313646 PMC: 9598039. DOI: 10.3389/fonc.2022.960109.


RNA interference screens discover proteases as synthetic lethal partners of PI3K inhibition in breast cancer cells.

Holzen L, Mitschke J, Schonichen C, Hess M, Ehrenfeld S, Boerries M Theranostics. 2022; 12(9):4348-4373.

PMID: 35673573 PMC: 9169373. DOI: 10.7150/thno.68299.


Analysis of the expression and prognostic value of MT1-MMP, β1-integrin and YAP1 in glioma.

Zhai Y, Sang W, Su L, Shen Y, Hu Y, Zhang W Open Med (Wars). 2022; 17(1):492-507.

PMID: 35350840 PMC: 8919829. DOI: 10.1515/med-2022-0449.


Comprehensive Analysis of the Immune and Prognostic Implication of MMP14 in Lung Cancer.

Zheng C, Lu Q, Zhang N, Jing P, Zhang J, Wang W Dis Markers. 2021; 2021:5917506.

PMID: 34868395 PMC: 8635876. DOI: 10.1155/2021/5917506.